Astrazeneca FY2026 EPS Forecast Boosted by Erste Group Bank

Astrazeneca Plc (NYSE:AZN) – Equities researchers at Erste Group Bank upped their FY2026 earnings per share estimates for Astrazeneca in a report released on Thursday, June 25th. Erste Group Bank analyst H. Engel now forecasts that the company will post earnings of $10.52 per share for the year, up from their previous estimate of $10.30. The consensus estimate for Astrazeneca’s current full-year earnings is $9.39 per share.

Astrazeneca (NYSE:AZN) last posted its earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.52 by $0.06. The firm had revenue of $15.29 billion for the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.

Several other equities research analysts also recently weighed in on the stock. DZ Bank raised shares of Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. Wall Street Zen upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. UBS Group reissued a “buy” rating on shares of Astrazeneca in a report on Friday, April 10th. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Astrazeneca in a research report on Tuesday. Finally, Jefferies Financial Group restated a “buy” rating on shares of Astrazeneca in a report on Friday, June 26th. Twelve investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $205.33.

Astrazeneca Trading Down 0.7%

NYSE:AZN opened at $189.66 on Wednesday. The stock has a market cap of $294.14 billion, a price-to-earnings ratio of 28.48, a PEG ratio of 1.66 and a beta of 0.25. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91. Astrazeneca has a 1 year low of $137.23 and a 1 year high of $212.71. The business has a fifty day moving average of $184.15 and a 200-day moving average of $187.47.

Institutional Trading of Astrazeneca

Large investors have recently added to or reduced their stakes in the business. Natixis Advisors LLC grew its stake in Astrazeneca by 14.3% during the 3rd quarter. Natixis Advisors LLC now owns 2,100,390 shares of the company’s stock valued at $161,142,000 after acquiring an additional 262,465 shares in the last quarter. Guardian Capital LP increased its holdings in shares of Astrazeneca by 31.0% in the 3rd quarter. Guardian Capital LP now owns 83,074 shares of the company’s stock valued at $6,373,000 after purchasing an additional 19,648 shares during the period. Legacy Capital Group California Inc. purchased a new stake in shares of Astrazeneca in the third quarter worth approximately $406,000. Focus Partners Advisor Solutions LLC lifted its position in shares of Astrazeneca by 53.8% in the third quarter. Focus Partners Advisor Solutions LLC now owns 10,307 shares of the company’s stock worth $875,000 after purchasing an additional 3,604 shares in the last quarter. Finally, Integral Health Asset Management LLC boosted its holdings in shares of Astrazeneca by 50.0% during the third quarter. Integral Health Asset Management LLC now owns 300,000 shares of the company’s stock worth $23,016,000 after purchasing an additional 100,000 shares during the period. 20.35% of the stock is currently owned by institutional investors.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.